Mai J. M. Chinapaw & Teatske M. AltenburgÂ
doi : 10.1038/s41574-022-00796-y
Volume 19 Issue 3, March 2023
Shimona StarlingÂÂ
Claire GreenhillÂÂ
Olivia TysoeÂÂ
Olivia TysoeÂÂ
Vincent Prevot & Ruben NogueirasÂ
Stepanka Pruhova & Petra DusatkovaÂ
Julia S. Brunner & Lydia W. S. FinleyÂ
doi : 10.1038/s41574-022-00773-5
Tumours exhibit notable metabolic alterations compared with their corresponding normal tissue counterparts. These metabolic alterations can support anabolic growth, enable survival in hostile environments and regulate gene expression programmes that promote malignant progression.
Lee-Ling Lim, Elaine Chow & Juliana C. N. ChanÂ
doi : 10.1038/s41574-022-00776-2
Patients with type 2 diabetes mellitus (T2DM) can have multiple comorbidities and premature mortality due to atherosclerotic cardiovascular disease, hospitalization with heart failure and/or chronic kidney disease.
Darleen A. Sandoval & Mary Elizabeth PattiÂ
doi : 10.1038/s41574-022-00757-5
Although promising therapeutics are in the pipeline, bariatric surgery (also known as metabolic surgery) remains our most effective strategy for the treatment of obesity and type 2 diabetes mellitus (T2DM). Of the many available options, Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG) are currently the most widely used procedures.
Jasleen Kaur & Elizabeth R. SeaquistÂ
doi : 10.1038/s41574-022-00762-8
Hypoglycaemia, which occurs when blood levels of glucose fall below what is considered a normal range, is a well-known complication of insulin therapy in individuals with type 1 diabetes mellitus. Despite advances in diabetes mellitus management, hypoglycaemia has continued to affect the majority of these individuals, leading to suboptimal care and decreased quality of life.
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟